Good afternoon :)
$
₹
Glaukos Corp

Glaukos Corp

GKOS

NYSE
Asset Logo

Glaukos Corp

GKOS

NYSE
$246.875.93% (+13.83)
$
₹
$246.875.93% (+13.83)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Large Cap

With a market cap of $14.1B the stock is ranked 788

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

19.60
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.95
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.64
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-24.6%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 13 analysts reports

Buy
12 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+4.04%

Earnings Growth

+142.03%

Rev. Growth

+53.82%

See Detailed Forecast

Company Profile

Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
40.95
40.95
1Y Return
13.03%
13.03%
Buy Reco %
82.14
82.14
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
37.74
37.74
1Y Return
7.61%
7.61%
Buy Reco %
83.33
83.33
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
52.82
52.82
1Y Return
10.52%
10.52%
Buy Reco %
76.47
76.47
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
23.69
23.69
1Y Return
16.08%
16.08%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
32.67
32.67
1Y Return
6.33%
6.33%
Buy Reco %
76.66
76.66
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 4.04% growth, versus a trailing 3-year CAGR of 53.84%.

2026
Current$233.04Baseline
Analyst Target - 1 year
Target$242.46+4.04%

All values in $

202220232024202520262027$96.16$153.01$209.86Target+4.04%
2026
Current$233.04Baseline
Analyst Target - 1 year
Target$242.46+4.04%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 53.82% growth, versus a trailing 3-year CAGR of 21.51%.

2025
Current$507.44Baseline
Forecast for Dec 2026
High$783.02+54.31%
Average$780.53+53.82%
Low$779.2+53.55%

All values in $ Million

202120222023202420252026294.01282.86314.71383.48507.44Low+53.55%Average+53.82%High+54.31%
2025
Current$507.44Baseline
Forecast for Dec 2026
High$783.02+54.31%
Average$780.53+53.82%
Low$779.2+53.55%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-1.52Baseline
Forecast for Dec 2026
High$0.85+155.92%
Average$0.64+142.03%
Low$0.21+113.82%

All values in $

202120222023202420252026-0.84-2.19-2.27-1.9-1.52Low+113.82%Average+142.03%High+155.92%
2025
Current$-1.52Baseline
Forecast for Dec 2026
High$0.85+155.92%
Average$0.64+142.03%
Low$0.21+113.82%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

143.1
-133.6
150.5
-19.7
185.6
-18.3
211
2
Q4 2025
Q1 2026
Q2 2026
Q3 2026
Revenue
Net Income
Financial YearQ2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026Q3 2026
Total Revenue95.6996.67105.49106.66124.12133.53143.12150.57185.61211.03
Net Income-50.54-21.40-33.58-18.14-19.65-16.23-133.65-19.78-18.372.01
Net Profit Margin-52.82%-22.14%-31.82%-17.01%-15.83%-12.15%-93.38%-13.13%-9.90%0.95%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Glaukos Corp -19.601.64
Abbott Laboratories40.953.591.51
Danaher Corporation37.743.041.32
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare GKOS with any stock or ETF
Compare GKOS with any stock or ETF
Comparing from
GKOS
ABT
DHR
Loading...

Frequently asked questions

  1. Glaukos Corp (GKOS) share price today is $246.87 as of November 5, 2026 at 2:29 AM IST. The stock touched a day high of $255.11 and a day low of $237.02.

  2. Glaukos Corp stock trades on NYSE under the ticker symbol GKOS.

  3. Glaukos Corp's market capitalization is $14.12B as of November 5, 2026 at 2:29 AM IST.

  4. Glaukos Corp's price-to-earnings (P/E) ratio is N/A as of November 4, 2026.

  5. Glaukos Corp's price-to-book (P/B) ratio is 19.60 as of November 4, 2026.

  6. Yes, You can buy Glaukos Corp shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Glaukos Corp shares in three steps: 1. Search Glaukos Corp on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Glaukos Corp trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Glaukos Corp (GKOS) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.0405 shares at the current price of $246.87.

Loading...